Items Tagged ‘neratinib’

July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer

By

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2


December 15th, 2014

Neratinib Continues to Show Activity in HER2-Positive Breast Cancer

By

Interim results from an ongoing Phase II clinical trial of neratinib were presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). Neratinib is an investigational, oral medication that targets HER2 as well as HER4 and the epidermal growth factor receptor (EGFR). Twenty to 25 percent of breast cancers overexpress (make too much of) a […]

View full entry

Tags: Breast Cancer, HER2, Metastatic Breast Cancer, neratinib, News, Recurrent Breast Cancer